Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy

• Main Authors: Griffiths, Kristin L. (Author), Ahmed, Mushtaq (Author), Das, Shibali (Author), Gopal, Radha (Author), Horne, William (Author), Connell, Terry D. (Author), Kolls, Jay K. (Author), Artyomov, Maxim N. (Author), Rangel-Moreno, Javier (Author), Khader, Shabaana A. (Author), Moynihan, Kelly Dare (Contributor), Irvine, Darrell J (Contributor)
• Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Massachusetts Institute of Technology. Department of Materials Science and Engineering (Contributor)
• Format: Article
• Language: English
• Published: Springer Nature, 2017-03-27T15:20:19Z.
• Subjects: Article
• Online Access: Get fulltext

 The development of a tuberculosis (TB) vaccine that induces sterilizing immunity to Mycobacterium tuberculosis infection has been elusive. Absence of sterilizing immunity induced by TB vaccines may be due to delayed activation of mucosal dendritic cells (DCs), and subsequent delay in antigen presentation and activation of vaccine-induced CD4[superscript +] T-cell responses. Here we show that pulmonary delivery of activated M. tuberculosis antigen-primed DCs into vaccinated mice, at the time of M. tuberculosis exposure, can overcome the delay in accumulation of vaccine-induced CD4[superscript +] T-cell responses. In addition, activating endogenous host CD103[superscript +] DCs and the CD40-CD40L pathway can similarly induce rapid accumulation of vaccine-induced lung CD4[superscript +] T-cell responses and limit early M. tuberculosis growth. Thus, our study provides proof of concept that targeting mucosal DCs can accelerate vaccine-induced T-cell responses on M. tuberculosis infection, and provide insights to overcome bottlenecks in TB vaccine efficacy.